amyloid-beta peptide 40 in plasma
Jump to navigation
Jump to search
Indications
Clinical significance
- predicts mortality in patients with acute coronary syndrome & NSTEMI[1]
- each standard deviation increase in plasma Abeta40 (67 pg/mL) at midlife associated with 15% higher risk of mild cognitive impairment or dementia 25 years later[2]
More general terms
Additional terms
Component of
References
- ↑ 1.0 1.1 1.2 Stamatelopoulos K, Mueller-Hennessen K, Georgiopoulos G. Amyloid-beta (1-40) and Mortality in Patients With Non-ST- Segment Elevation Acute Coronary Syndrome: A Cohort Study. Ann Intern Med. 2018. May 22 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29799975 <Internet> http://annals.org/aim/article-abstract/2681795/amyloid-1-40-mortality-patients-non-st-segment-elevation-acute
- ↑ 2.0 2.1 George J Midlife Blood Amyloid Levels Tied to Late-Life Dementia. Plasma biomarker may predict Alzheimer's s progression decades before symptoms appear. MedPage Today August 5, 2021 https://www.medpagetoday.com/neurology/alzheimersdisease/93919
Sullivan KJ, Blackshear C, Simino J et al Association of Midlife Plasma Amyloid-beta Levels With Cognitive Impairment in Late Life: The ARIC Neurocognitive Study. Neurology. 2921 Aug 4 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34349010 https://n.neurology.org/content/early/2021/08/04/WNL.0000000000012482